This innovation story began more than 30 years ago, when a Purdue University biomedical engineering team discovered the regenerative properties of porcine small intestinal submucosa (SIS) and other extracellular matrix materials.
In 1995, based on research supporting the versatility and effectiveness of SIS, Cook Group Inc. licensed the technology from the Purdue Research Foundation and established Cook Biotech, Inc. to develop and commercialize the new biomaterials. This collaboration bridged the two worlds of a well-established, innovative medical company and a prestigious research university.
Since then, Cook Biotech has developed and manufactured products for clinical applications ranging from dura repair to diabetic foot ulcers, from dental repair to hernia repair. To date, Cook Biotech has shipped more than 6 million products through their global network of partners and distributors.
Nexsis Biosciences was created to identify, develop and deliver applications of this unique technology platform to address a wide range of unmet clinical needs.
SIS acts as a scaffold material to support the population of the ECM with patient-derived cells
SIS is gradually replaced by the patient’s own tissue and cells
The patient’s own collagen gradually matures into a stable structure that has long-term strength but is entirely the patient’s own